Lung Large Cell Carcinoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Lung Large Cell Carcinoma

MalaCards integrated aliases for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 12 15
Large Cell Carcinoma of Lung 12 72
Large Cell Lung Carcinoma 12 17
Large Cell Lung Cancer 55


External Ids:

Disease Ontology 12 DOID:4556
NCIt 50 C4450
UMLS 72 C0345958

Summaries for Lung Large Cell Carcinoma

MalaCards based summary : Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to pulmonary large cell neuroendocrine carcinoma and lung cancer. An important gene associated with Lung Large Cell Carcinoma is ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Integrated Breast Cancer Pathway and Tyrosine Kinases / Adaptors. The drugs Sirolimus and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and brain, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 75 Large-cell carcinoma (LCC) is a heterogeneous group of undifferentiated malignant neoplasms that lack... more...

Related Diseases for Lung Large Cell Carcinoma

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Lung Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Related Disease Score Top Affiliating Genes
1 pulmonary large cell neuroendocrine carcinoma 32.1 SYP ROS1
2 lung cancer 11.6
3 large cell neuroendocrine carcinoma 11.6
4 lung mixed small cell and squamous cell carcinoma 11.5
5 large cell carcinoma 10.4
6 subependymal glioma 10.1 SYP MTOR
7 benign ependymoma 10.1 SYP MTOR
8 atrial septal defect 4 10.1 MTOR ABL1
9 thrombocytosis 10.0
10 pulmonary tuberculosis 10.0
11 subependymal giant cell astrocytoma 10.0 SYP MTOR
12 central nervous system benign neoplasm 10.0 SYP MTOR
13 lethal congenital contracture syndrome 10.0
14 adenosquamous carcinoma 10.0
15 vasculitis 10.0
16 immunodeficiency, common variable, 10 9.9
17 squamous cell carcinoma 9.9
18 cerebrofacial arteriovenous metameric syndrome 9.9
19 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.8
20 rhabdoid tumor predisposition syndrome 1 9.8
21 pleurisy 9.8
22 pneumothorax 9.8
23 adenocarcinoma 9.8
24 rhabdoid cancer 9.8
25 pleural empyema 9.8
26 large cell carcinoma with rhabdoid phenotype 9.8
27 autoimmune disease 9.8
28 retinal detachment 9.8
29 aland island eye disease 9.8
30 reflex sympathetic dystrophy 9.8
31 lung cancer susceptibility 3 9.8
32 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
33 small cell carcinoma 9.8
34 cutaneous t cell lymphoma 9.8
35 dermatomyositis 9.8
36 respiratory failure 9.8
37 algoneurodystrophy 9.8
38 neuroendocrine carcinoma 9.8
39 calcinosis 9.8
40 rectum cancer 9.8
41 rectum adenocarcinoma 9.8
42 inner ear disease 9.8
43 choriocarcinoma 9.8
44 spindle cell carcinoma 9.8
45 keratinizing squamous cell carcinoma 9.8
46 basaloid squamous cell carcinoma 9.8
47 lymphoepithelioma-like carcinoma 9.8
48 b-cell lymphoma 9.8
49 orbital disease 9.8
50 scotoma 9.8

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:

Diseases related to Lung Large Cell Carcinoma

Symptoms & Phenotypes for Lung Large Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.06 MTOR
2 Decreased viability GR00173-A 11.06 ANKK1
3 Decreased viability GR00221-A-1 11.06 ABL1 BTK MTOR ROS1 CAMK4 NME1
4 Decreased viability GR00221-A-2 11.06 ABL1 EPHA5 TTN ANKK1 BTK ROS1
5 Decreased viability GR00221-A-3 11.06 ABL1 EPHA5 BTK
6 Decreased viability GR00221-A-4 11.06 EPHA5 TTN ANKK1 BTK MTOR
7 Decreased viability GR00301-A 11.06 BTK CAMK4
8 Decreased viability GR00342-S-1 11.06 ABL1 TTN MTOR ROS1
9 Decreased viability GR00342-S-2 11.06 ABL1 MTOR
10 Decreased viability GR00342-S-3 11.06 ABL1 EPHA5 TTN
11 Decreased viability GR00402-S-2 11.06 ABL1 EPHA5 TTN ANKK1 BTK MTOR
12 Decreased substrate adherent cell growth GR00193-A-1 10.35 BTK ATR BRSK1 ROS1 TTN
13 Decreased substrate adherent cell growth GR00193-A-2 10.35 ABL1 ROS1 ALPK3 MTOR TRRAP
14 Decreased substrate adherent cell growth GR00193-A-4 10.35 ABL1 ANKK1 BTK
15 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.95 ABL1 ANKK1 ATR BRSK1 BTK MTOR
16 Decreased vesicular stomatitis virus (VSV) infection GR00356-A-1 9.87 ANKK1 ATR BRSK1 CAMK4 MTOR TRRAP
17 Decreased cell proliferation GR00353-A 9.61 ANKK1 MTOR TRRAP
18 Increased cell viability after pRB stimulation GR00230-A-1 9.55 ABL1 ANKK1 BRSK1 BTK CAMK4
19 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 9.26 ATR MTOR ROS1 TRRAP
20 Transferrin accumulation in the perinuclear area GR00356-A-3 8.92 ATR CAMK4 MTOR TRRAP

MGI Mouse Phenotypes related to Lung Large Cell Carcinoma:

# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.7 ABL1 ALPK3 ATR BRSK1 BTK CAMK4
2 normal MP:0002873 9.17 ABL1 ATR BRSK1 CAMK4 MTOR SYP

Drugs & Therapeutics for Lung Large Cell Carcinoma

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4 Antifungal Agents Phase 4
5 Antibiotics, Antitubercular Phase 4
Vinblastine Approved Phase 3 865-21-4 241903 13342
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
Etoposide Approved Phase 3 33419-42-0 36462
Bevacizumab Approved, Investigational Phase 3 216974-75-3
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
leucovorin Approved Phase 3 58-05-9 143 6006
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
Lenograstim Approved, Investigational Phase 3 135968-09-1
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Tirapazamine Investigational Phase 3 27314-97-2
18 Topoisomerase Inhibitors Phase 3
19 Etoposide phosphate Phase 3
20 Antineoplastic Agents, Immunological Phase 3
21 Mitogens Phase 3
22 Antibodies Phase 3
23 Antibodies, Monoclonal Phase 3
24 Immunoglobulins Phase 3
25 Immunoglobulin G Phase 3
26 Endothelial Growth Factors Phase 3
27 Folic Acid Antagonists Phase 3
28 Nucleic Acid Synthesis Inhibitors Phase 3
29 Vitamin B9 Phase 3
30 Folate Phase 3
31 Vitamin B Complex Phase 3
32 Anti-Bacterial Agents Phase 3
33 Angiogenesis Inhibitors Phase 3
34 Angiogenesis Modulating Agents Phase 3
35 Anti-Inflammatory Agents Phase 3
36 Analgesics Phase 3
37 Cyclooxygenase 2 Inhibitors Phase 3
38 Peripheral Nervous System Agents Phase 3
39 Analgesics, Non-Narcotic Phase 3
40 Anti-Inflammatory Agents, Non-Steroidal Phase 3
41 Antirheumatic Agents Phase 3
42 Cyclooxygenase Inhibitors Phase 3
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
Cobalt Approved, Experimental Phase 2 7440-48-4 104729
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
3 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
4 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
5 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
6 A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer Completed NCT00003685 Phase 3
7 Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness Completed NCT00003117 Phase 3 carboplatin;paclitaxel
8 Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
9 Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
10 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
11 A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
13 A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
14 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial Active, not recruiting NCT00030771 Phase 3 Chemotherapy
15 A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
16 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
17 Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
18 Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study. Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
19 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
20 A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
21 Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
22 A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
23 A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
24 A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
25 A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
26 A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
27 Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy Regimen With Bi-Weekly Docetaxel in the Treatment of Metastatic or Locally Advanced Non-Small Cell Lung Cancer in Patients Over the Age of 70 Unknown status NCT00227708 Phase 2 docetaxel
28 A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
29 First Line Treatment of Stage IIIb/IV Non Small Cell (NSC) Lung Cancer With a Bimonthly Administration of a Combination of Cisplatin-Gemcitabine Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride
30 Phase II Study Of Gemcitabine And Docetaxel In Patients With Inoperable Stage IIIB Or IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
31 Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase Ⅱa Trial Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
32 A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
33 A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor Unknown status NCT01175096 Phase 1, Phase 2 RAD001 (everolimus, Afinitor®)
34 Phase II Study Of TLK286 For The Treatment Of Advanced Non-Small Cell Lung Cancer Completed NCT00036920 Phase 2 canfosfamide hydrochloride
35 A Phase II Study Of Temozolomide In The Treatment Of Patients With Metastatic Non-Small Cell Lung Cancer Completed NCT00006877 Phase 2 temozolomide
36 Preoperative Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2) Completed NCT00003231 Phase 2 cisplatin;docetaxel
37 Phase II Study of CCNU (Lomustine) in Patients With Advanced Non-Small Cell Lung Cancer and Aberrant Hypermethylation of the MGMT Gene Completed NCT00293280 Phase 2 lomustine
38 A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
39 Phase II Trial of Gemcitabine/Paraplatin® (Carboplatin) Followed by Taxol® (Paclitaxel) in Patients With Performance Status = 2,3 or Other Significant Co-Morbidity (HIV Infection or s/p Organ Transplantation) in Advanced Non-Small Cell Lung Cancer Completed NCT00276588 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
40 Vinorelbine Plus Bevacizumab as First Line Therapy in Patients ≥ 70 Years of Age With Stage IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
41 Preoperative Chemoradiotherapy In Non-Small Cell Lung Cancer (NSCLC) Patients With Operable Stage IIIB Disease: A Prospective Phase II Trial Completed NCT00030810 Phase 2 Taxotere/Cisplatin
42 Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
43 A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Medically Inoperable Stage I/II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
44 A Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT) For Inoperable Stage I/II Non-Small Cell Lung Cancer (NSCLC) Completed NCT00346320 Phase 2
45 Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
47 A Phase II, Open Label Study of Gefitinib (IRESSA) in Treatment-Naïve Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer and Somatic Activating Mutations in the Epidermal Growth Factor Receptor Completed NCT00411047 Phase 2 gefitinib
48 A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2) Completed NCT00661193 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel
49 A Phase II Study Evaluating a Maintenance Strategy of Gleevce® (Imatinib Mesylate) and Bevacizumab in Patients With Advanced, Non-squamous, Non-small Cell Lung Cancer, Following Completion of First-line Chemotherapy With Bevacizumab Completed NCT00425646 Phase 2 imatinib mesylate
50 Multicenter Phase II Trial of Gefitinib (Iressa™) First Line Therapy Followed by Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Completed NCT00217698 Phase 2 cisplatin;gefitinib;gemcitabine hydrochloride

Search NIH Clinical Center for Lung Large Cell Carcinoma

Genetic Tests for Lung Large Cell Carcinoma

Anatomical Context for Lung Large Cell Carcinoma

MalaCards organs/tissues related to Lung Large Cell Carcinoma:

Lung, Lymph Node, Brain, Endothelial, Thyroid, Breast, Bone

Publications for Lung Large Cell Carcinoma

Articles related to Lung Large Cell Carcinoma:

(show top 50) (show all 217)
# Title Authors PMID Year
Cancer-associated Retinopathy with Neuroendocrine Combined Large-cell Lung Carcinoma and Adenocarcinoma: A Case Report. 38
31327819 2019
Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma. 38
31360195 2019
Doxycycline inhibits electric field-induced migration of non-small cell lung cancer (NSCLC) cells. 38
31147570 2019
Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients. 38
31179087 2019
Connexin43 Suppresses Lung Cancer Stem Cells. 38
30717421 2019
Clinical characteristics and prognosis of basaloid squamous cell carcinoma of the lung: a population-based analysis. 38
31106047 2019
Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma. 38
30166013 2018
Metachronous gastric metastasis from lung primary, with synchronous pancreatic neuroendocrine carcinoma. 38
29988660 2018
Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations. 38
29570944 2018
Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria. 38
29525405 2018
Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin. 38
29541373 2018
The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro. 38
29230631 2018
Unravelling the Long Non-Coding RNA Profile of Undifferentiated Large Cell Lung Carcinoma. 38
29657301 2018
Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer. 38
28176646 2018
Personalized siRNA-Nanoparticle Systemic Therapy using Metastatic Lymph Node Specimens Obtained with EBUS-TBNA in Lung Cancer. 38
28993508 2018
Laparoscopic Splenectomy for Splenic Metastasis from Primary Lung Carcinoma. 38
29732229 2018
Correlation between STK33 and the pathology and prognosis of lung cancer. 38
29085482 2017
TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis. 38
28789440 2017
Comparison of human lung cancer cell radiosensitivity after irradiations with therapeutic protons and carbon ions. 38
27633574 2017
[Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. 38
28468033 2017
[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation]. 38
28219201 2017
A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity. 38
27894849 2017
Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. 38
28790845 2017
Immune-associated proteins with potential in vivo anti-tumor activities are upregulated in lung cancer cells treated with umbelliprenin: A proteomic approach. 38
28105238 2016
[Two Cases of Small Intestinal Metastasis of Lung Cancer]. 38
28133150 2016
Differentiating brain metastases from different pathological types of lung cancers using texture analysis of T1 postcontrast MR. 38
26621795 2016
Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer. 38
27301951 2016
Discovery of 'click' 1,2,3-triazolium salts as potential anticancer drugs. 38
27679544 2016
Blood-borne miRNA profile-based diagnostic classifier for lung adenocarcinoma. 38
27507195 2016
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. 38
26942444 2016
Treatment of lung large cell neuroendocrine carcinoma. 38
26943800 2016
Four Cu(ii) complexes based on antitumor chelators: synthesis, structure, DNA binding/damage, HSA interaction and enhanced cytotoxicity. 38
27071545 2016
[Large-cell lung carcinoma by the 2015 WHO classification: a clinicopathologic analysis of 93 cases]. 38
27033385 2016
Brachial metastatic plexopathy as the inaugural manifestation of lung cancer: multimodality imaging. 38
30460024 2016
[A clinical review of 3 cases of children with bronchial tumor]. 38
26696483 2015
Digging Deep for New Compounds from the Compass Plant, Silphium laciniatum. 38
26287548 2015
Lung transthoracic ultrasound elastography imaging and guided biopsies of subpleural cancer: a preliminary report. 38
24951615 2015
Large cell lung carcinoma with rhabdoid phenotype: Report of a rare entity presenting with chest wall involvement. 38
26458655 2015
Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology. 38
25793929 2015
Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report. 38
26170921 2015
Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. 38
25937073 2015
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. 38
25638031 2015
Association of structural modifications with bioactivity in three new copper(II) complexes of Schiff base ligands derived from 5-chlorosalicylaldehyde and amino acids. 38
25771239 2015
Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers. 38
25776027 2015
A retrospective analysis of the clinicopathological characteristics of large cell carcinoma of the lung. 38
25452802 2015
Bilateral diffuse uveal melanocytic proliferation with good clinical response to plasmapheresis and treatment of the primary tumor. 38
25383840 2015
Isolation and characterization of a new cytotoxic dihydrophenanthrene from Dioscorea membranacea rhizomes and its activity against five human cancer cell lines. 38
25149021 2014
Relationships between level of lipid peroxidation products and expression of Nrf2 and its activators/ inhibitors in non-small cell lung cancer tissue. 38
26461337 2014
Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells. 38
25312819 2014
Caveolin-1 promotes an invasive phenotype and predicts poor prognosis in large cell lung carcinoma. 38
24831264 2014

Variations for Lung Large Cell Carcinoma

Cosmic variations for Lung Large Cell Carcinoma:

9 (show top 50) (show all 732)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6953383 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 18
2 COSM6966579 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 18
3 COSM6980872 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 18
4 COSM95548 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 18
5 COSM95544 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 18
6 COSM6980399 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.233G>A p.W78* 11:32434909-32434909 18
7 COSM6938307 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1156A>T p.K386* 11:32392044-32392044 18
8 COSM95531 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 18
9 COSM95521 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 18
10 COSM21262 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 18
11 COSM95485 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 18
12 COSM95476 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 18
13 COSM96265 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64I 17:60301699-60301699 18
14 COSM94159 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 8:102326590-102326590 18
15 COSM94158 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 8:102305221-102305221 18
16 COSM6983597 U2AF1 lung,NS,carcinoma,undifferentiated carcinoma c.319G>C p.D107H 21:43095467-43095467 18
17 COSM95420 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 19:10350838-10350838 18
18 COSM12945 TTBK1 lung,NS,carcinoma,large cell carcinoma c.2417C>T p.S806F 6:43283157-43283157 18
19 COSM6942934 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.1922C>T p.S641L 14:81143980-81143980 18
20 COSM6953382 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.937A>C p.K313Q 14:81142995-81142995 18
21 COSM6966576 TSHR lung,NS,carcinoma,undifferentiated carcinoma c.412C>T p.L138F 14:81091088-81091088 18
22 COSM6980873 TSC2 lung,NS,carcinoma,undifferentiated carcinoma c.1840G>T p.A614S 16:2071510-2071510 18
23 COSM6980394 TSC1 lung,NS,carcinoma,undifferentiated carcinoma c.694G>T p.E232* 9:132921406-132921406 18
24 COSM12943 TRRAP lung,NS,carcinoma,large cell carcinoma c.8015C>T p.P2672L 7:98976613-98976613 18
25 COSM12942 TRPM6 lung,NS,carcinoma,large cell carcinoma c.3021G>C p.W1007C 9:74782752-74782752 18
26 COSM6980408 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1193C>T p.P398L 16:2173978-2173978 18
27 COSM6940747 TRAF7 lung,NS,carcinoma,undifferentiated carcinoma c.1287C>G p.Y429* 16:2174274-2174274 18
28 COSM95390 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 1:211356392-211356392 18
29 COSM10808 TP53 lung,NS,carcinoma,large cell carcinoma c.488A>G p.Y163C 17:7675124-7675124 18
30 COSM10659 TP53 lung,NS,carcinoma,large cell carcinoma c.817C>T p.R273C 17:7673803-7673803 18
31 COSM10887 TP53 lung,NS,carcinoma,large cell carcinoma c.833C>G p.P278R 17:7673787-7673787 18
32 COSM11188 TP53 lung,NS,carcinoma,large cell carcinoma c.412G>C p.A138P 17:7675200-7675200 18
33 COSM21593 TP53 lung,NS,carcinoma,large cell carcinoma c.358A>T p.K120* 17:7676011-7676011 18
34 COSM10779 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>T p.R273L 17:7673802-7673802 18
35 COSM22908 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.376-1G>T p.? 17:7675237-7675237 18
36 COSM10770 TP53 lung,NS,carcinoma,large cell carcinoma c.1045G>T p.E349* 17:7670664-7670664 18
37 COSM11232 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.842A>G p.D281G 17:7673778-7673778 18
38 COSM11333 TP53 lung,NS,carcinoma,large cell carcinoma c.499C>T p.Q167* 17:7675113-7675113 18
39 COSM45304 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.375+1G>A p.? 17:7675993-7675993 18
40 COSM10726 TP53 lung,NS,carcinoma,large cell carcinoma c.856G>A p.E286K 17:7673764-7673764 18
41 COSM10768 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 17:7675077-7675077 18
42 COSM11196 TP53 lung,NS,carcinoma,large cell carcinoma c.734G>T p.G245V 17:7674229-7674229 18
43 COSM11564 TP53 lung,NS,carcinoma,large cell carcinoma c.742C>G p.R248G 17:7674221-7674221 18
44 COSM10810 TP53 lung,NS,carcinoma,large cell carcinoma c.725G>T p.C242F 17:7674238-7674238 18
45 COSM11392 TP53 lung,NS,carcinoma,large cell carcinoma c.800G>C p.R267P 17:7673820-7673820 18
46 COSM10742 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.578A>G p.H193R 17:7674953-7674953 18
47 COSM11073 TP53 lung,NS,carcinoma,large cell carcinoma c.1024C>T p.R342* 17:7670685-7670685 18
48 COSM43559 TP53 lung,NS,carcinoma,large cell carcinoma c.517G>T p.V173L 17:7675095-7675095 18
49 COSM43896 TP53 lung,NS,carcinoma,large cell carcinoma c.818G>C p.R273P 17:7673802-7673802 18
50 COSM44398 TP53 lung,NS,carcinoma,large cell carcinoma c.682G>A p.D228N 17:7674281-7674281 18

Expression for Lung Large Cell Carcinoma

Search GEO for disease gene expression data for Lung Large Cell Carcinoma.

Pathways for Lung Large Cell Carcinoma

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.32 MTOR ATR ABL1
2 11.09 ROS1 EPHA5 BTK ABL1

GO Terms for Lung Large Cell Carcinoma

Cellular components related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.7 TTN TRRAP NME1 MYO18B MTOR CAMK4
2 perinuclear region of cytoplasm GO:0048471 9.02 ROS1 NME1 EPHA5 BTK ABL1

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 endocytosis GO:0006897 9.7 SYP NME1 ABL1
2 peptidyl-serine phosphorylation GO:0018105 9.65 MTOR CAMK4 ATR
3 protein phosphorylation GO:0006468 9.65 TTN ROS1 MTOR EPHA5 CAMK4 BTK
4 protein autophosphorylation GO:0046777 9.62 MTOR BTK ATR ABL1
5 peptidyl-tyrosine phosphorylation GO:0018108 9.55 TTN ROS1 EPHA5 BTK ABL1
6 long-term memory GO:0007616 9.54 MTOR CAMK4
7 regulation of actin cytoskeleton organization GO:0032956 9.54 MTOR EPHA5 ABL1
8 positive regulation of protein phosphorylation GO:0001934 9.51 MTOR ABL1
9 regulation of protein kinase activity GO:0045859 9.49 TTN MTOR
10 cardiac muscle fiber development GO:0048739 9.46 TTN MYO18B
11 phosphorylation GO:0016310 9.44 TTN TRRAP ROS1 NME1 MTOR EPHA5
12 regulation of osteoclast differentiation GO:0045670 9.43 MTOR CAMK4
13 peptidyl-tyrosine autophosphorylation GO:0038083 9.43 ROS1 BTK ABL1
14 cardiac muscle cell development GO:0055013 9.4 MTOR ALPK3

Molecular functions related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activity GO:0004674 9.87 TTN MTOR CAMK4 BRSK1 ATR ANKK1
2 protein kinase activity GO:0004672 9.85 TTN ROS1 MTOR EPHA5 CAMK4 BTK
3 protein tyrosine kinase activity GO:0004713 9.77 TTN ROS1 EPHA5 BTK ABL1
4 ATP binding GO:0005524 9.77 TTN ROS1 NME1 MYO18B MTOR EPHA5
5 kinase activity GO:0016301 9.44 TTN TRRAP ROS1 NME1 MTOR EPHA5
6 gamma-tubulin binding GO:0043015 9.4 NME1 BRSK1
7 transferase activity GO:0016740 10.07 TTN TRRAP ROS1 NME1 MTOR EPHA5

Sources for Lung Large Cell Carcinoma

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....